Steven A. Middleton

4.6k total citations · 1 hit paper
63 papers, 3.7k citations indexed

About

Steven A. Middleton is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Steven A. Middleton has authored 63 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 25 papers in Molecular Biology and 12 papers in Organic Chemistry. Recurrent topics in Steven A. Middleton's work include Cancer-related Molecular Pathways (17 papers), HER2/EGFR in Cancer Research (7 papers) and Urinary Bladder and Prostate Research (7 papers). Steven A. Middleton is often cited by papers focused on Cancer-related Molecular Pathways (17 papers), HER2/EGFR in Cancer Research (7 papers) and Urinary Bladder and Prostate Research (7 papers). Steven A. Middleton collaborates with scholars based in United States, France and United Kingdom. Steven A. Middleton's co-authors include Linda K. Jolliffe, Dana L. Johnson, Oded Livnah, Ian A. Wilson, E.A. Stura, Peter J. Connolly, Stuart L. Emanuel, Linda S. Mulcahy, Evan R. Kantrowitz and William J. Dower and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Steven A. Middleton

63 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

2012 455 citations Jianguo Zhi, Steven A. Middleton et al. profile →

Peers

Countries citing papers authored by Steven A. Middleton

Since Specialization

Citations

This map shows the geographic impact of Steven A. Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven A. Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven A. Middleton more than expected).

Fields of papers citing papers by Steven A. Middleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven A. Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven A. Middleton. The network helps show where Steven A. Middleton may publish in the future.

Co-authorship network of co-authors of Steven A. Middleton

This figure shows the co-authorship network connecting the top 25 collaborators of Steven A. Middleton. A scholar is included among the top collaborators of Steven A. Middleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven A. Middleton. Steven A. Middleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors 2015 ·Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Anthony W. Tolcher, M. Beeram, John Nemunaitis, Glen J. Weiss, Kapil N. Bhalla, Manish Agrawal, Gwen Nichols, Steven A. Middleton, (unknown), Nenad Sarapa, Richard Peck, Jianguo Zhi	37
2	Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors 2009 ·Medicinal Chemistry ·Shengjian Li, George Chiu, Virginia Pulito, Jingchun Liu, Peter J. Connolly, Steven A. Middleton	3
3	Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases 2008 ·Bioorganic & Medicinal Chemistry Letters ·Guozhang Xu, (unknown), Terry V. Hughes, (unknown), Peter J. Connolly, M.C. Abad, Michael P. Neeper, Geoffrey T. Struble, Barry A. Springer, Stuart L. Emanuel, Robert H. Gruninger, Niranjan B. Pandey, Mary Adams, (unknown), Angel R. Fuentes‐Pesquera, Steven A. Middleton, Lee M. Greenberger	48
4	α_1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms 2008 ·Expert Opinion on Therapeutic Patents ·George Chiu, Peter J. Connolly, Steven A. Middleton, Shengjian Li, Virginia Pulito, Jingchun Liu, Ellen W. Baxter, Allen B. Reitz	5
5	A novel 5-[1,3,4-oxadiazol-2-yl]-N-aryl-4,6-pyrimidine diamine having dual EGFR/HER2 kinase activity: Design, synthesis, and biological activity 2008 ·Bioorganic & Medicinal Chemistry Letters ·Terry V. Hughes, Guozhang Xu, Steven K. Wetter, Peter J. Connolly, Stuart L. Emanuel, Prabha Karnachi, Scott R. Pollack, Niranjan B. Pandey, Mary Adams, (unknown), Steven A. Middleton, Lee M. Greenberger	24
6	Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1) 2007 ·Bioorganic & Medicinal Chemistry Letters ·Shenlin Huang, Ronghua Li, Peter J. Connolly, Stuart L. Emanuel, Angel R. Fuentes‐Pesquera, Mary Adams, Robert H. Gruninger, (unknown), Steven A. Middleton, Jeremy Davis, David Moffat	11
7	Aminocyclohexylsulfonamides: Discovery of metabolically stable α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) 2007 ·Bioorganic & Medicinal Chemistry Letters ·George Chiu, Shengjian Li, (unknown), Peter J. Connolly, Sean Peng, Kathe Stauber, Virginia Pulito, Jingchun Liu, Steven A. Middleton	5
8	(Phenylpiperazinyl)cyclohexylureas: Discovery of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) 2007 ·Bioorganic & Medicinal Chemistry Letters ·George Chiu, Shengjian Li, Peter J. Connolly, Virginia Pulito, Jingchun Liu, Steven A. Middleton	9
9	1-Arylpiperazinyl-4-cyclohexylamine derived isoindole-1,3-diones as potent and selective α-1a/1d adrenergic receptor ligands 2007 ·Bioorganic & Medicinal Chemistry Letters ·Shengjian Li, George Chiu, Virginia Pulito, Jingchun Liu, Peter J. Connolly, Steven A. Middleton	17
10	Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors 2006 ·Bioorganic & Medicinal Chemistry Letters ·Shenlin Huang, Ronghua Li, Peter J. Connolly, Stuart L. Emanuel, Steven A. Middleton	19
11	Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor 2006 ·Bioorganic & Medicinal Chemistry Letters ·Shenlin Huang, Ronghui Lin, Yang Yu, Yanhua Lü, Peter J. Connolly, George Chiu, Shengjian Li, Stuart L. Emanuel, Steven A. Middleton	101
12	8-(Heteroaryl)phenalkyl-1-Phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as Opioid Receptor Modulators 2005 ·Medicinal Chemistry ·Alfonzo D. Jordan, Michael J. Orsini, Steven A. Middleton, Peter J. Connolly, Douglas E. Brenneman, (unknown), Allen B. Reitz	5
13	3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation 2005 ·Bioorganic & Medicinal Chemistry Letters ·Ronghui Lin, Yanhua Lü, Steven K. Wetter, Peter J. Connolly, Ignatius J. Turchi, William V. Murray, Stuart L. Emanuel, Robert H. Gruninger, Angel R. Fuentes‐Pesquera, Mary Adams, Niranjan B. Pandey, (unknown), Steven A. Middleton, Linda K. Jolliffe	21
14	Shared and Unique Determinants of the Erythropoietin (EPO) Receptor Are Important for Binding EPO and EPO Mimetic Peptide 1999 ·Journal of Biological Chemistry ·Steven A. Middleton, Francis P. Barbone, Dana L. Johnson, Robin L. Thurmond, Yun You, Frank J. McMahon, (unknown), Oded Livnah, Jennifer Tullai, Francis X. Farrell, Mark A. Goldsmith, Ian A. Wilson, Linda K. Jolliffe	47
15	Identification of a Critical Ligand Binding Determinant of the Human Erythropoietin Receptor 1996 ·Journal of Biological Chemistry ·Steven A. Middleton, Dana L. Johnson, (unknown), Frank J. McMahon, Alexander M Collins, Jennifer Tullai, Robert H. Gruninger, Linda K. Jolliffe, Linda S. Mulcahy	49
16	Structural consequences of the replacement of Glu239 by Gln in the catalytic chain ofEscherichia coli aspartate transcarbamylase 1990 ·Journal of Molecular Biology ·Patrick Tauc, Patrice Vachette, Steven A. Middleton, Evan R. Kantrowitz	24
17	Structure of a single amino acid mutant of aspartate carbamoyltransferase at 2.5 .ANG. resolution: implications for the cooperative mechanism 1989 ·Biochemistry ·J. Eric Gouaux, William N. Lipscomb, Steven A. Middleton, Evan R. Kantrowitz	11
18	Kinetic consequences of site-specific mutation of Glu-239 → Gln in E. coli aspartate transcarbamylase: comparison with catalytic subunits and Phe-240 mutant enzyme 1989 ·Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology ·Yuchiong Hsuanyu, Frederick C. Wedler, Steven A. Middleton, Evan R. Kantrowitz	7
19	Relationship between domain closure and binding, catalysis, and regulation in Escherichia coli aspartate transcarbamylase 1988 ·Biochemistry ·Moncef Ladjimi, Steven A. Middleton, Kerry Kelleher, Evan R. Kantrowitz	61
20	Propagation of allosteric changes through the catalytic-regulatory interface of Escherichia coli aspartate transcarbamylase 1988 ·Biochemistry ·Wei Xu, Mark Pitts, Steven A. Middleton, Kerry Kelleher, Evan R. Kantrowitz	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact